 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 November 1993 | Volume 119 Issue 10 | Pages 963-968
Objective: To determine the effects of a short course of a low dose of a glucocorticoid agent on bone mass.
Design: Double-blind, placebo-controlled, randomized study.
Setting: Outpatient clinic of a university hospital.
Patients: Forty patients with active rheumatoid arthritis.
Intervention: All patients started receiving intramuscular gold salts. In addition, they were randomly allocated to receive either prednisone or placebo. The initial dose was 10 mg/d, which was tapered between weeks 12 and 20. Thereafter, patients were followed for an additional 24 weeks.
Measurements: Lumbar bone mineral density was measured with dual-energy, quantitative computed tomography in a trabecular and a cortical region of interest.
Results: Despite favorable effects on disease activity and functional capacity, trabecular bone mineral density decreased in the prednisone-treated patients between baseline and week 20 (mean change, –8.2%;95% CI, –12.7% to –3.7%;P = 0.001). Little change was found in the placebo-treated patients (P > 0.2), and the prednisone group had a greater mean bone loss than the placebo group (9.5%; CI, 3.4% to 15.6%; P = 0.003). After discontinuation of prednisone, an increase was found in trabecular bone mineral density between weeks 20 and 44 (mean change, 5.3%; CI, 0.7% to 9.9%; P = 0.03). Little change was found after withdrawal of placebo (P > 0.2). The mean improvement in the prednisone group was 6.8% (CI, 0.8% to 12.8%; P = 0.03) greater than for placebo. In both treatment groups, cortical bone mineral density did not change markedly in either period (P
Conclusions: Low doses of glucocorticoid agents cause marked vertebral trabecular bone loss in the initial months of therapy in patients with active rheumatoid arthritis. After discontinuation of treatment, this bone loss seems to be (partially) reversible.
Author and Article Information
From the University Hospital Nijmegen, the Netherlands.
ARTICLE
Low-Dose Prednisone Induces Rapid Reversible Axial Bone Loss in Patients with Rheumatoid Arthritis
A Randomized, Controlled Study
0.2).
Requests for Reprints: Roland F.J.M. Laan, MD, Department of Rheumatology, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, the Netherlands.
Grant Support: By the Program for the Stimulation of Health Research, and by the Dutch League against Rheumatism.
This article has been cited by other articles:
|
|
 |
|
  T. P. van Staa, P. Geusens, B. Zhang, H. G. M. Leufkens, A. Boonen, and C. Cooper Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids Rheumatology, March 1, 2007; 46(3): 460 - 466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. P. DA SILVA, J. W. G. JACOBS, and J. W. J. BIJLSMA Revisiting the Toxicity of Low-Dose Glucocorticoids: Risks and Fears Ann. N.Y. Acad. Sci., June 1, 2006; 1069(1): 275 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J A P Da Silva, J W G Jacobs, J R Kirwan, M Boers, K G Saag, L B S Ines, E J P de Koning, F Buttgereit, M Cutolo, H Capell, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data Ann Rheum Dis, March 1, 2006; 65(3): 285 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bhattacharya, M. Rahman, J. Banu, R. A. Lawrence, H. S. McGuff, I.R. Garrett, M. Fischbach, and G. Fernandes Inhibition of Osteoporosis in Autoimmune Disease Prone MRL/Mpj-Faslpr Mice by N-3 Fatty Acids J. Am. Coll. Nutr., June 1, 2005; 24(3): 200 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Scanlon, J. E. Connett, R. A. Wise, D. P. Tashkin, T. Madhok, M. Skeans, P. C. Carpenter, W. C. Bailey, A. S. Buist, M. Eichenhorn, et al. Loss of Bone Density with Inhaled Triamcinolone in Lung Health Study II Am. J. Respir. Crit. Care Med., December 15, 2004; 170(12): 1302 - 1309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Dovio, L. Perazzolo, G. Osella, M. Ventura, A. Termine, E. Milano, A. Bertolotto, and A. Angeli Immediate Fall of Bone Formation and Transient Increase of Bone Resorption in the Course of High-Dose, Short-Term Glucocorticoid Therapy in Young Patients with Multiple Sclerosis J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 4923 - 4928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Gluck and G. Colice Recognizing and Treating Glucocorticoid-Induced Osteoporosis in Patients With Pulmonary Diseases Chest, May 1, 2004; 125(5): 1859 - 1876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H Forsblad d'Elia, A Larsen, E Waltbrand, G Kvist, D Mellstrom, T Saxne, C Ohlsson, E Nordborg, and H Carlsten Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis Ann Rheum Dis, July 1, 2003; 62(7): 617 - 623. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Yeap and D. J. Hosking Management of corticosteroid-induced osteoporosis Rheumatology, October 1, 2002; 41(10): 1088 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Biskobing COPD and Osteoporosis Chest, February 1, 2002; 121(2): 609 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Pincus, T. Sokka, and C. M. Stein Are Long-Term Very Low Doses of Prednisone for Patients with Rheumatoid Arthritis as Helpful as High Doses Are Harmful? Ann Intern Med, January 1, 2002; 136(1): 76 - 78. [Full Text] [PDF]
|
|
|
|
|
|
A. C. Verhoeven, M. Boers, J. M. te Koppele, W. H. van der Laan, H. M. Markusse, P. Geusens, and S. van der Linden Bone turnover, joint damage and bone mineral density in early rheumatoid arthritis treated with combination therapy including high-dose prednisolone Rheumatology, November 1, 2001; 40(11): 1231 - 1237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Yood, L. R. Harrold, L. Fish, J. Cernieux, S. Emani, E. Conboy, and J. H. Gurwitz Prevention of Glucocorticoid-Induced Osteoporosis: Experience in a Managed Care Setting Arch Intern Med, May 28, 2001; 161(10): 1322 - 1327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Naganathan, G. Jones, P. Nash, G. Nicholson, J. Eisman, and P. N. Sambrook Vertebral Fracture Risk With Long-term Corticosteroid Therapy: Prevalence and Relation to Age, Bone Density, and Corticosteroid Use Arch Intern Med, October 23, 2000; 160(19): 2917 - 2922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. K Kvien, G. Haugeberg, T. Uhlig, J. A Falch, J. I Halse, W. F Lems, B. A C Dijkmans, and A. D Woolf Data driven attempt to create a clinical algorithm for identification of women with rheumatoid arthritis at high risk of osteoporosis Ann Rheum Dis, October 1, 2000; 59(10): 805 - 811. [Abstract] [Full Text]
|
|
|
|
 |
|
 M E LLOYD, T D SPECTOR, and R HOWARD Osteoporosis in neurological disorders J. Neurol. Neurosurg. Psychiatry, May 1, 2000; 68(5): 543 - 547. [Full Text]
|
|
|
|
|
|
D. Jardinet, C. Lefebvre, G. Depresseux, M. Lambert, J.-P. Devogelaer, and F. A. Houssiau Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine Rheumatology, April 1, 2000; 39(4): 389 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. R. Reid Glucocorticoid Osteoporosis: Reid IR Glucocorticoid osteoporosis J Intensive Care Med 1999, 14231-242 J Intensive Care Med, September 1, 1999; 14(5): 231 - 242. [PDF]
|
|
|
|
 |
|
 A. S. Krasner Glucocorticoid-Induced Adrenal Insufficiency JAMA, August 18, 1999; 282(7): 671 - 676. [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Niewoehner, M. L. Erbland, R. H. Deupree, D. Collins, N. J. Gross, R. W. Light, P. Anderson, N. A. Morgan, and The Department of Veterans Affairs Cooperative Stu Effect of Systemic Glucocorticoids on Exacerbations of Chronic Obstructive Pulmonary Disease N. Engl. J. Med., June 24, 1999; 340(25): 1941 - 1947. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Roux, P. Oriente, R. Laan, R. A. Hughes, J. Ittner, S. Goemaere, O. Di Munno, J. M. Pouillès, S. Horlait, and B. Cortet Randomized Trial of Effect of Cyclical Etidronate in the Prevention of Corticosteroid-Induced Bone Loss J. Clin. Endocrinol. Metab., April 1, 1998; 83(4): 1128 - 1133. [Abstract] [Full Text]
|
|
|
|
|
|
C. E. MCEVOY, K. E. ENSRUD, E. BENDER, H. K. GENANT, W. YU, J. M. GRIFFITH, and D. E. NIEWOEHNER Association between Corticosteroid Use and Vertebral Fractures in Older Men with Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., March 1, 1998; 157(3): 704 - 709. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. F Lems, J. W G Jacobs, J. W J Bijlsma, G. J M van Veen, H. H M L Houben, H. C M Haanen, M. I Gerrits, and H. J M van Rijn Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis? Ann Rheum Dis, June 1, 1997; 56(6): 357 - 363. [Abstract] [Full Text]
|
|
|
|
 |
|
 Corticosteroid-induced osteoporosis DTB, November 1, 1996; 34(11): 84 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Fries, G. Singh, D. Porter, A.A. Deodhar, A.D. Woolf, and J. R. Kirwan Glucocorticoids and Joint Destruction in Rheumatoid Arthritis N. Engl. J. Med., December 7, 1995; 333(23): 1569 - 1570. [Full Text]
|
|
|
|
 |
|
 M. J. Paul-Clark, L. Mancini, P. Del Soldato, R. J. Flower, and M. Perretti Potent antiarthritic properties of a glucocorticoid derivative, NCX-1015, in an experimental model of arthritis PNAS, February 5, 2002; 99(3): 1677 - 1682. [Abstract] [Full Text] [PDF]
|
|
Article
